Publications by authors named "A V Al'sakini"
Background: Ventricular tachycardia (VT) in patients with cardiac sarcoidosis (CS) can lead to sudden cardiac death. The role of ventricular tachycardia ablation (VTA) in CS has been investigated in a few small, single-center, and larger observational studies, but the evidence still needs to be provided. This study aimed to investigate the clinical outcomes of VTA in patients with CS admitted with a diagnosis of VT.
View Article and Find Full Text PDFArticle Synopsis
- Heart failure with preserved ejection fraction (HFpEF) is common, representing 40%-50% of new heart failure cases, but effective treatment options are still uncertain, with SGLT2 inhibitors emerging as a potential solution.
- The study analyzed data from 8 randomized controlled trials involving over 16,500 participants, concluding that SGLT2 inhibitors like empagliflozin and dapagliflozin reduce the risk of cardiovascular hospitalizations without significantly affecting overall mortality rates.
- The findings suggest that SGLT2 inhibitors are safe and beneficial for HFpEF patients, regardless of factors like kidney function or comorbid conditions.
Article Synopsis
- The study assesses the awareness, attitudes, and practices related to breast self-examination (BSE) among female patients with breast cancer in Baghdad Medical City.
- Of the 100 participants, 71 were aware of BSE, mainly through social media, but many struggled to perform it correctly due to a lack of understanding.
- Significant connections were found between timely BSE initiation and its proper execution, as well as an association between performing BSE correctly and the early detection of breast cancer.
Dementia is a chronic progressive cognitive decline illness that results in functional impairment. Vascular dementia (VaD), second only to Alzheimer's disease (AD), is one of the most prevalent forms of dementia in the elderly (aged over 65 years), with a varied presentation and unpredictable disease development caused by cerebrovascular or cardiovascular illness. To get a better understanding of the changes occurring in the brain and to drive therapy efforts, new biomarkers for early and precise diagnosis of AD and VaD are required.
View Article and Find Full Text PDF